BioNTech (NASDAQ:BNTX) CEO Sells $4,628,250.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 45,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00. Following the transaction, the chief executive officer owned 813,209 shares of the company’s stock, valued at approximately $83,638,545.65. The trade was a 5.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.

BioNTech Trading Down 4.9%

Shares of BNTX traded down $5.10 during trading hours on Tuesday, hitting $98.66. 1,103,851 shares of the stock were exchanged, compared to its average volume of 1,114,410. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The business has a 50-day moving average of $96.82 and a 200-day moving average of $95.61. The firm has a market capitalization of $24.95 billion, a P/E ratio of -12.60 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same period last year, the company posted ($1.60) EPS. The business’s revenue was down 59.5% compared to the same quarter last year. On average, research analysts expect that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Berenberg Bank cut their target price on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. BMO Capital Markets downgraded BioNTech from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $128.00 to $105.00 in a research note on Tuesday. Finally, Morgan Stanley cut their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently modified their holdings of BNTX. Flossbach Von Storch SE purchased a new position in shares of BioNTech during the second quarter valued at approximately $207,142,000. BNP Paribas Financial Markets grew its position in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares during the period. Bank of America Corp DE grew its position in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after buying an additional 166,432 shares during the period. GSK plc purchased a new stake in BioNTech during the fourth quarter worth about $84,711,000. Finally, First Trust Advisors LP raised its position in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.